IL166010A0 - Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1 - Google Patents

Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1

Info

Publication number
IL166010A0
IL166010A0 IL16601004A IL16601004A IL166010A0 IL 166010 A0 IL166010 A0 IL 166010A0 IL 16601004 A IL16601004 A IL 16601004A IL 16601004 A IL16601004 A IL 16601004A IL 166010 A0 IL166010 A0 IL 166010A0
Authority
IL
Israel
Prior art keywords
mip
selective inhibitors
piperidine derivatives
receptor ccr1
1alpha
Prior art date
Application number
IL16601004A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL166010A0 publication Critical patent/IL166010A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16601004A 2002-07-18 2004-12-27 Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1 IL166010A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18
PCT/IB2003/002876 WO2004009550A1 (fr) 2002-07-18 2003-07-07 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison mip-1alpha a son recepteur ccr1

Publications (1)

Publication Number Publication Date
IL166010A0 true IL166010A0 (en) 2006-01-15

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16601004A IL166010A0 (en) 2002-07-18 2004-12-27 Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1

Country Status (24)

Country Link
US (1) US20040063759A1 (fr)
EP (1) EP1534677A1 (fr)
JP (1) JP2005537279A (fr)
KR (1) KR20050021497A (fr)
CN (1) CN1668592A (fr)
AP (1) AP2005003200A0 (fr)
AR (1) AR040583A1 (fr)
AU (1) AU2003242941A1 (fr)
BR (1) BR0312946A (fr)
CA (1) CA2492651A1 (fr)
EC (1) ECSP055547A (fr)
HN (1) HN2003000222A (fr)
IL (1) IL166010A0 (fr)
IS (1) IS7614A (fr)
MA (1) MA27326A1 (fr)
MX (1) MXPA05000380A (fr)
OA (1) OA12885A (fr)
PA (1) PA8575901A1 (fr)
PE (1) PE20040666A1 (fr)
TN (1) TNSN05014A1 (fr)
TW (1) TW200402416A (fr)
UY (1) UY27897A1 (fr)
WO (1) WO2004009550A1 (fr)
ZA (1) ZA200500067B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
US7493363B2 (en) 2001-09-19 2009-02-17 Microsoft Corporation Peer-to-peer group management and method for maintaining peer-to-peer graphs
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
EP1531822B1 (fr) 2002-06-12 2009-08-05 ChemoCentryx Inc Derives de piperazine 1-aryl-4-substitues utilises en tant qu'antagonistes du ccr1 dans le traitement de l'inflammation et des troubles immunitaires
CA2492110A1 (fr) * 2002-07-18 2004-01-29 Pfizer Products Inc. Derives de piperidine bicycliques utilises comme antagonistes du recepteur de chimiokine ccr1
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
SI1907374T1 (sl) 2005-07-26 2012-11-30 Glaxo Group Ltd Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
WO2007073432A2 (fr) 2005-10-11 2007-06-28 Chemocentryx, Inc. Derives de la piperidine et procedes d’utilisation
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
WO2009051244A1 (fr) * 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2010077915A1 (fr) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Nouveaux composés utiles comme ligands de récepteur de chémokine cc
WO2015091645A1 (fr) 2013-12-18 2015-06-25 Basf Se Composés d'azole transportant un substituant dérivé d'imine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (fr) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
CA2373942A1 (fr) * 1999-05-18 2000-11-23 Teijin Limited Remedes ou prophylactase contre les maladies associees a des chimiokines
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
CA2453383C (fr) * 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Derives de piperidine utilises en tant qu'antagonistes du recepteur n-methyl-d-aspartate (nmda)

Also Published As

Publication number Publication date
CA2492651A1 (fr) 2004-01-29
PA8575901A1 (es) 2004-07-20
KR20050021497A (ko) 2005-03-07
MA27326A1 (fr) 2005-05-02
US20040063759A1 (en) 2004-04-01
MXPA05000380A (es) 2005-03-31
HN2003000222A (es) 2004-11-23
OA12885A (en) 2006-09-15
JP2005537279A (ja) 2005-12-08
AP2005003200A0 (en) 2005-03-31
ZA200500067B (en) 2005-11-02
TNSN05014A1 (fr) 2007-05-14
ECSP055547A (es) 2005-03-10
EP1534677A1 (fr) 2005-06-01
IS7614A (is) 2004-12-23
AU2003242941A1 (en) 2004-02-09
UY27897A1 (es) 2004-02-27
TW200402416A (en) 2004-02-16
PE20040666A1 (es) 2004-09-25
CN1668592A (zh) 2005-09-14
WO2004009550A1 (fr) 2004-01-29
BR0312946A (pt) 2005-07-12
AR040583A1 (es) 2005-04-13

Similar Documents

Publication Publication Date Title
IL166010A0 (en) Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
IL173398A0 (en) Pyridyl derivatives and their use as therapeutic agents
IL182527A0 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EP1656378A4 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
PL378331A1 (pl) Tetracykliczne pochodne benzamidowe i sposoby ich stosowania
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
IL174702A0 (en) Spirocyclic heterocyclic derivatives and methods of their use
AU2003259735A8 (en) Small-mer compositions and methods of use
IL177650A0 (en) Isoquinoline derivatives and methods of use thereof
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
IL174334A0 (en) Use of chk1 inhibitors to control cell proliferation
EP1703907A4 (fr) Compositions et procedes permettant de traiter des etats pathologiques recurrents
AU2003215756A1 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
IL174497A0 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
IL175179A0 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
PL380189A3 (pl) Azolidynokarbonitryle i ich zastosowanie jako inhibitory DPP-IV
EP1750697A4 (fr) Procédés et compositions utilisant des médicaments d'inhibition de la cytokine pour le traitement et la gestion de cancers et d'autres maladies
EP1601348A4 (fr) Compositions et methodes presentant une activite therapeutique amelioree
GB0611789D0 (en) Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
AU2003231019A8 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use